|
Mechanismthymosin beta 4 modulators |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
The objective of this study is to compare the efficacy and safety of RGN-137 topical gel with that of placebo gel for treatment of junctional epidermolysis bullosa (JEB) or dystrophic epidermolysis bullosa (DEB).
100 Clinical Results associated with Lenus Therapeutics, LLC
0 Patents (Medical) associated with Lenus Therapeutics, LLC
100 Deals associated with Lenus Therapeutics, LLC
100 Translational Medicine associated with Lenus Therapeutics, LLC